Edition:
United States

ChemoCentryx Inc (CCXI.OQ)

CCXI.OQ on NASDAQ Stock Exchange Global Select Market

7.29USD
20 Sep 2017
Change (% chg)

-- (--)
Prev Close
$7.29
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
47,828
52-wk High
$10.80
52-wk Low
$4.89

Chart for

About

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving... (more)

Overall

Beta: 1.55
Market Cap(Mil.): $355.07
Shares Outstanding(Mil.): 48.71
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.91 16.25
EPS (TTM): -- -- --
ROI: -- 15.14 14.87
ROE: -- 16.37 13.89

BRIEF-ChemoCentryx qtrly basic and diluted net loss per share $0.19

* ChemoCentryx reports second quarter 2017 financial results and recent highlights

Aug 08 2017

BRIEF-Chemocentryx Q1 revenue $8.2 million

* Chemocentryx Inc- Expects to utilize cash and cash equivalents between $50 million and $55 million in 2017

May 10 2017

BRIEF-Chemocentryx receives FDA orphan drug designation for Avacopan in treatment of debilitating kidney disease

* Chemocentryx receives fda orphan drug designation for avacopan in the treatment of debilitating kidney disease c3 glomerulopathy (c3g)

Mar 22 2017

Competitors

Earnings vs. Estimates